It is expected that targeting the disruption of pathways mediated by FVC, FEV1, CRP, and IL-6 can reduce the adverse impact of obesity on acute bronchitis and pneumonia, thereby alleviating the burden of LRTIs. Here, IL6 is linked to obesity disorder.